bluuebunny/crossref_metadata_2025_split huggingface dataset:
(100) PREVALENCE AND CLINICAL PROFILE OF VERY YOUNG MEN WITH ERECTILE DYSFUNCTION – FINDINGS FROM A REAL-LIFE CROSS-SECTIONAL STUDY
Authors: Dr. Edoardo Pozzi , Dr. Federico Belladelli , Dr. Simone Cilio , Dr. Giuseppe Fallara , Dr. Christian Corsini , Dr. Francesco Lanzaro , Dr. Alessandro Bertini , Dr. Massimiliano Raffo , Fausto Negri , Ludovica Cella , Margherita Fantin , Dr. Luigi Candela , Dr. Paolo Capogrosso , Dr. Luca Boeri , Dr. Alessia d'Arma , Prof. Francesco Montorsi , Prof. Andrea Salonia 
Published: July 2023

Abstract

Objectives
To assess and compare the sociodemographic and clinical characteristics of young (30-40 yr) and very young (18-29 yr) ED patients and to explore the changes in patterns of reported ED in men with ≤ 29 yr over a 17-yr period at a single academic centre.

Methods
Data from 519 consecutive patients &lt; 40 yr complaining of ED between 2005 and 2022 were analysed. All patients completed the International IIEF. Patients were segregated into two groups: 18-29 vs. 30-40 yr. Descriptive statistics tested sociodemographic and clinical differences between the two cohorts. Linear regression and local polynomial models were applied to explore and graphically display the trend of assessing 18-29 vs. 30-40-yr ED patients over the analysed time-frame.

Results
Overall, 191 (36.8%) were &lt; 29 yr and 328 (63.2%) were 30-40 yr. The two groups did not differ in terms of commonly recognised ED risk factors. Rates of severe ED according to IIEF-EF did not differ between the two cohorts at presentation (20.9% vs. 18.6%). Younger patients were less likely to report a stable partner (45.5% vs. 61.6%, p&lt;0.001), to suffer of arterial hypertension (3.7% vs. 8.5%) and had lower median BMI (22.8 vs. 24.5 kg/m2) but higher total testosterone (5.6 vs. 5.1 ng/mL), all p&lt;0.05 respectively. At linear regression analysis, patients assessed throughout the 17-yr time frame were progressively younger (Coeff –0.09, p&lt;0.001). Figure 1 graphically displays the probability of assessing younger patients over the 17-yr time-frame with median (IQR) age in 2005 of 34 (32-34) yr vs. 29 (25-32) yr in 2022.

Conclusions
Among young men seeking first medical help for new onset ED, one out of three has less than 29 yr. Of those, one out of five reports criteria suggestive of severe ED. The probability of assessing very young men complaining of ED (18-29 yr) has worrisomely increased over the last two decades roughly.

Conflicts of Interest
N/A
(58) “THE COMBINATION OF PRP AND STEM CELLS IMPROVES ERECTILE FUNCTION AFTER PENILE RESTORATION FOR PEYRONIE'S DISEASE WITH GRAFTS”
Authors: Dr. Christos Fliatouras , Dr. Nikolaos Karypidis , Dr. Theodoros Spinos , Dr. Konstantinos Konstantinidis 
Published: July 2023

Abstract

Objectives
The purpose of this presentation is to report the role of the combination of mesotherapy (Platelet Rich Plasma, PRP) and stem cells in improving erectile function after the restoration of Peyronie's disease with grafts (tachosil).

Methods
Erectile dysfunction is the most frequent and severe complication after penile grafting. Patients with large penile curvature underwent penile surgery with tachosil by a single high-volume Urological surgeon who washighly experienced in the field of Andrology. All patients were older than 42 years and had a penile curvature which was greater than 45°, attributed to Peyronie's disease. Some patients had a synchronous hourglass deformity, while many of them presented several comorbidities. All patients underwent repair of their curvaturewith tachosil graft, with or without simultaneous plaque removal, and were subjected to the combinationtreatment of PRP and stem cells, either intraoperatively or postoperatively, while some of them underwent shockwave therapy too.

Results
All of them were able to have sex with or without the use of PDE5 inhibitors or penile self-injections.

Conclusions
We thus concluded that the intraoperative or postoperative administration of the combination of mesotherapy and stem cells seems to be particularly efficient, regarding improvement of erectile dysfunction which resultsfrom penile grafting for Peyronie's disease with tachosil. Penile grafting is a particularly important surgical approach for Peyronie’s disease, as it manages to preserve penile length during penile curvature reconstruction.

Conflicts of Interest
The authors declare no conflicts of interest.
(249) DO ANTIPLATELET DRUGS USE CONTRIBUTE TO CLINICAL OUTCOMES IN PATIENTS RECEIVING PENILE LOW-INTENSITY SHOCK WAVE THERAPY (LI-SWT) FOR ERECTILE DYSFUNCTION?
Authors: Dr. Serdar Geyik , Dr. Mutlu Deger , Dr. Nebil Akdogan , Dr. Nazim A Kankilic , Dr. Ismail O Yilmaz , Prof. Ibrahim A Aridogan 
Published: July 2023

Abstract

Objectives
Low-intensity extracorporeal shock wave therapy (Li-SWT) is one of the recommended treatment options in patients with erectile dysfunction (ED). Li-SWT is safe in patients using antiplatelet drugs (APs), however, there are no specific studies on the contribution of APs use to clinical improvement in erectile function. We aimed to evaluate the early clinical results of Li-SWT administration and whether the use of APs had an additional positive contribution to clinical improvement and safe in ED patients.

Methods
Patients with ED for more than 6 months despite using (5 mg/day) PDE5i were included in our study. Patients treated with Li-SWT and using PDE5i were classified as Group 1, patients treated with Li-SWT and using APs and using PDE5i were considered Group 2. The evaluation results of the International Index of Erectile Function-Erectile Function Area (IIEF-EF) in all patients baseline and after treatment were examined.

Results
There are 25 patients in each group. Analysis of IIEF-EF scores showed significant increases in both groups after treatment [group 1 (p=0.001); group 2 (p=0.001)]. When the IIEF-EF scores of the groups before and after the treatment were compared with each other; it was shown that baseline scores were similar (p=0.746) and that APs use had no statistically significant effect on post-treatment scores (p=0.613) No side effects were seen in APs.

Conclusions
This study showed that penile Li-SWT significantly increases the IIEF-EF scores and response of (5 mg/day) PDE5i in ED patients and safe, also in AP users. However, Using AP in Li-SWT does not contribute positively to clinical results.

Conflicts of Interest
The authors declares that there is no conficts of interest.
(274) VACUUM DEVICE USAGE AFTER A RADICAL PROSTATECTOMY
Authors: Matthew Megson , Chi-Ying Li 
Published: July 2023

Abstract

Objectives
Within the first year after a radical prostatectomy (RALP) the majority of men experience erectile dysfunction (ED) and penile shortening.
One the treatments option is a vacuum device. Raina et al and Kohler et al showed that early use of vacuum device (VED) after a RALP facilitates early sexual intercourse, early patient sexual satisfaction and helped to maintain penile size.
The aim of this audit is to assess the effectiveness and compliance of VED use in patients after RALP.

Methods
The patients who were attending the andrology clinic for ED treatment after a RALP at our Hospital were asked short questions (Table 1).

Results
46 patients are included and asked the audit questions.
The median follow-up time was 16 months (min=3, max=21).
96% (n=44) wanted a VED in their management plan and 87% (n=40) have received one.
85% (n=34) of these with the devise were prescribed via their GP, 7.5% (n=3) self-funded and 7.5% (n=3) had prescribed at the hospital.
77.5% (n=31) were using only for rehabilitation, 2.5% using only for intercourse and 20% (n=8) for both.
77.5% (n=31) told us it created an erection. However, 25% (n=10) of the patients stopped using the device during the follow-up period. 30% (n=3) due to pain, 40% (n=4) because they felt it didn’t work and the rest either for psychological reasons or they didn’t need it anymore.
They had used it for a median of 5 months (min=2, max=8 months) before stopping.

Conclusions
A large proportion of men undergoing RALP are motivated to use a VED.
Although a high proportion found it effective, only a small proportion use it for intercourse and the compliance rate is low raising the question of the cost effectiveness of routine recommendation of this device.
Improved patient support and motivation is required for encouraging long term use.

Conflicts of Interest
No conflict of interest to disclose.
(78) SURGICAL AND FUNCTIONAL OUTCOMES OF THE A MODIFIED SHORTENING CORPOROPLASTY FOR CONGENITAL AND ACQUIRED PENILE CURVATURE
Authors: Marco Falcone , Mirko Preto , Lorenzo Cirigliano , Massimiliano Timpano , Carlo Ceruti , Federica Peretti , Ilaria Ferro , Natalia Plamadeala , Prof. Paolo Gontero 
Published: July 2023

Abstract

Objectives
Nesbit corporoplasty was proposed to address penile curvature (PC), both congenital (CPC) and acquired (APC). The study evaluates surgical, functional, and patient-reported outcomes (PROs) of a modified shortening corporoplasty.

Methods
Single center retrospective analysis of patients undergone modified corporoplasty from May 2005 to June 2022 was carried out. Penile complete straightening, operative time, intra and postoperative complications were considered as surgical outcomes. Functional outcomes were evaluated through the International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP, items 2-3) questionnaires administered preoperatively and 12 months after surgery. Moreover, PROs were assessed through an "ad hoc" created questionnaire.

Results
118 patients with complete clinical data were included in the study. CPC was noted in 76 patients whilst APC was present in 42 patients. The most frequent curvature was ventral (48.3%). Preoperative mean PC was 60° (SD ±21). The median follow-up time was 125 months (IQR 35-150). Median operative time was 120 minutes (IQR 105-140). 80% of the patients reported a straight penis while a minor residual curvature (&lt;20°) was detected in 16.2%. IIEF and SEP 2-3 scores improved in both groups. Long-term de novo postoperative erectile dysfunction was observed in 3% of CPC patients and in 39% of APC cases (P = 0.001). Multivariate analysis revealed that etiology (APC), patient age (&gt;35 years), and postoperative complications represented independent risk factors for the development of postoperative erectile dysfunction. Postoperative complications occurred in 10.2% of patients. 26.4% of patients declared to be dissatisfied of postoperative penile length, with a higher incidence in the APC group (P = .001). Overall, a significant improvement in sexual life was observed in both categories.

Conclusions
The modified shortening corporoplasty may represent an excellent option for PC correction, with limited complications and high patients satisfaction rate. Overall, APC patients may experience less favorable outcomes when compared to CPC.

Conflicts of Interest
The authors have no conflicts of interest to disclose.
(169) MEDICAL TREATMENT OF PEYRONIE’S DISEASE WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM: PROSPECTIVE OUTCOMES FROM 150 PATIENTS
Authors: Dr. Aliki Germanou , Dr. Edouard Fortier , Prof. Rodolphe Thuret , Dr. Antoine Faix 
Published: July 2023

Abstract

Objectives
To evaluate the efficacy and safety of collagenase Clostridium Histolyticum (CCH; Xiapex®) in patients with acute or chronic phase of Peyronie’s disease.

Methods
Patients 18 years of age or older with Peyronie’s disease were enrolled to a retrospective study. All patients received at least one injection of CCH by a single surgeon. The angle of curvature before and after treatment was measured. Peyronie’s Disease Questionnaire (PDQ) and its sub-scores, PDQ-PS (psychological symptoms), PDQ-PP (penile pain) and PDQ-BD (bother disease) were completed to assess at the baseline and at the last observation carried forward. In between injections, patients applied the modeling protocol at home.

Results
Overall, 150 patients were enrolled. The penile curvature improved from 53.07° ± 16.35° before treatment to 38.65° ± 16.08° after treatment, representing a mean change of 14.42°. There was a statistical improvement in all three PDQ domains independently of the initial penile curvature, PDQ-PS (-1 (-6;2), p=0.005), PDQ-PP (-1 (-6;0), p&lt;0.001) and PDQ-BD (-2 (-6;0), p&lt;0.001)) from baseline to last observation carried forward. CCH was well tolerated. One adverse event was reported, managed conservatively.

Conclusions
CCH is a safe and effective injectable drug for all curvature directions regardless the phase of the disease. Millions of PD patients can benefit by this treatment modality and its return in European market should be reexamined.

Conflicts of Interest
No conflicts of interest
(332) THE EFFECT OF PDE5-INHIBITORS IN THE MANAGEMENT OF PEYRONIE’S DISEASE IN THE ACTIVE PHASE: A RETROSPECTIVE COHORT STUDY
Authors: Dr. Emil Durukan , Rune H Kraglund , Dr. Shad A Rashid , Dr. Tine Thorkilgaard , Christian F S Jensen , Prof. Mikkel Fode 
Published: July 2023

Abstract

Objectives
Experimental models and preliminary human trials have implied that continuous treatment with PDE-5 inhibitors may be a viable treatment of Peyronie’s disease (PD) in the active phase. The purpose of this study is to assess the effect of PDE-5 inhibitors on penile curvature in the management of PD in the active phase.

Methods
We performed a retrospective cohort study of patients with PD in the active phase seen between 2017 and 2021. Patients were included if they had at least two recorded visits with curvature measurements. Patient characteristics and PD characteristics including pain, treatment and, curvatures at each visit were registered. The primary outcome was the change in penile curvature between visits in patients receiving daily PDE-5 inhibitor compared to patients receiving no treatment.

Results
135 patients were identified, with 102 (75.6%) receiving treatment with daily PDE-5 inhibitors and 33 (24.4%) receiving no treatment. The mean age in the treatment group and control group was 58 (±10.1) and 58.4 (±13.5) years, respectively. The mean time between the onset of symptoms and the first clinical visit was 11.3 (±8.6) months in the treatment group and 13.3 (±18.7) months in the control group. The mean change in penile curvature between the first and last observations in the treatment group and control group was 1.67° (±9.7) and -0.3° (±12.9), respectively (p = 0.9). A multivariate analysis controlling for baseline curvature and time from onset and the first visit showed no statistically significant differences in penile curvature changes (-0.28, 95% CI [-4.4, 3.8] p = 0.9).

Conclusions
Continuous PDE-5 inhibitor treatment appeared to have no influence on the progression of PD in the active phase. The main limitation of the study is its retrospective nature. This may have masked a potential effect as it can be speculated that patients with clinically significant improvements in curvature are less likely to show up for follow-up visits.

Conflicts of Interest
The authors declare no conflicts of interest.
(183) FROM WATERLOO TO THE GREAT WALL: A RETROSPECTIVE, MULTICENTER STUDY ON THE CLINICAL PRACTICE AND CULTURAL ATTITUDES IN THE MANAGEMENT OF PREMATURE EJACULATION, IN CHINA
Authors: Dr. Andrea Sansone , Jianlin Yuan , Guangdong Hou , Lei Zhang , Ming Gao , Zhe Zhang , Jiang Hui , Fu Wang , Jun Guo , Qiang Geng , Ming Wang , Xiansheng Zhang , Xi Yu , Zhang Yan , Jin-Chuan Liu , Yong-Gong Duan , Dinesh Nagrale , Zhiguo Chen , Prof. Emmanuele A Jannini ,   on behalf of the MAPS-GOSH (Marco Polo Study Group on Sexual Health)
Published: July 2023

Abstract

Objectives
To carry out a real-life retrospective, multicenter survey on the prevalence, subtype, and proposed treatments of premature ejaculation in China.

Methods
Real-life data were provided by 8 major Centers from China, selected as active in basic and clinical research on PE and participating to international meetings of sexual medicine and andrology. Centers provided a filled survey containing relevant information concerning PE prevalence, pathogenesis and treatment.

Results
In 2019, among 156,486 patients coming to the centers, 32,667 visits having PE as the chief complaint were performed (20.9%). Almost all patients received treatment prescriptions (32,641 patients, 99.92%); 23,273 patients came back for a follow-up visit in the subsequent 12 months (71.2% of those who initially received treatment). Dapoxetine, either alone or in combination with another therapy, was the most prevalent treatment, prescribed to 22,767 patients (69.7% of treated patients), followed by Traditional Chinese medicine (TCM) (39.4%). At follow-up, 8174 patients were unsatisfied with treatment, and a new treatment was proposed (35.12%). Dapoxetine was the best treatment, with an overall 27.1% switching rate when used either alone or in combination: while the switching rate for Dapoxetine alone was 44.2%, the association of the same drug with psychotherapy resulted in much lower rates (19.5%) and reached a minimum of 12% when also combined with TCM demonstrating how cultural aspects and medical attitudes may dramatically impact on the therapy of a multifaceted, complex, and culture-grounded sexual symptom such as PE.

Conclusions
Taking switching rates as surrogate markers of treatment failure, this real-life study – the largest in the field - shows that in a more patient-oriented (as in Chinese medical culture), and less symptom-oriented (as in Western medical attitudes), Dapoxetine is a successful treatment for PE patients, with higher reliability when used alone or as part of combined and integrated therapies.

Conflicts of Interest
EAJ is or has been a speaker and/or paid consultant for Bayer, Ibsa, Lundbeck, Menarini, Merk-Serono, Otsuka, Pfizer, Shionogi, and Viatris. AS has been a paid consultant for Menarini. All others declare not to have any competing interest for the present manuscript.
(275) THE ROLE OF TESTOSTERONE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS:RESULTS FROM A META-ANALYSIS STUDY
Authors: Dr. Walter Vena , Dr. Nicola Bianchi , Dr. Francesca Frizza , Prof. Giulia Rastrelli , Prof. Linda Vignozzi , Prof. Arcangelo Barbonetti , Prof. Edoardo Mannucci , Dr. Alessandra Sforza , Prof. Mario Maggi , Dr. Alessandro Pizzocaro , Dr. Giovanni Corona 
Published: July 2023

Abstract

Objectives
Type 2 diabetes mellitus [T2DM] and hypogonadism are common conditions afflicting the aging male, often present together. The specific role of testosterone [T] replacement therapy [TRT] on glycometabolic profile and body composition, particularly in patients with T2DM, is still the object of an intense debate. The aim of the present study is to meta-analyze the role of TRT in T2DM considering all placebo and non-placebo-controlled randomized clinical trials [RCTs].

Methods
An extensive Medline, Embase and Cochrane search was performed. We did not employ search software but hand-searched bibliographies of retrieved papers for additional references. All RCTs studies investigating the impact of TRT on glycometabolic outcomes without any restriction were included.

Results
Overall, 12 studies were available including 684 patients with a mean follow-up of 38.4 weeks. These trials differ in basal TT levels and type of T preparation used. In addition, only 10 were placebo controlled

Conclusions
The overall data analysis indicates that TRT favorably affects glycemic control in diabetic subjects reducing fasting glycaemia, HbA1c and HOMA index and decreasing triglyceride levels and fat mass. All these differences were confirmed when only placebo-controlled studies were evaluated, with the exception for HbA1c decrease, where only a trend towards a decrease was apparent. Conversely no effects on TRT on erectile function was observed.

Conflicts of Interest
No conflict of interest to delcare.
(87) PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED STUDY COMPARING MICRO TESE AND TESE PERFORMED WITH SURGICAL LOUPES IN MALE PATIENTS WITH NON-OBSTRUCTIVE AZOOSPERMIA
Authors: Dr. Mirko Preto , Marco Falcone , Dr. Boeri Luca , Prof. Giorgio I Russo , Dr. Massimiliano Timpano , Dr. Federica Peretti , Dr. Lorenzo Cirigliano , Dr. Ilaria Ferro , Dr. Natalia Plamadeala , Prof. Carlo Ceruti , Prof. Paolo Gontero 
Published: July 2023

Abstract

Objectives
To compare surgical outcomes and retrieval rates between conventional microsurgical-assisted testicular sperm extraction (m-Tese) AND TESE PERFORMED WITH SURGICAL LOUPES (L-TESE) IN ADULT MALES AFFECTED BY NON-OBSTRUCTIVE AZOOSPERMIA (NOA).

Methods
A multicentric prospective randomized trial (Ethics Committee N°: 202/2022) was conducted starting in March 2022 including NOA-affected patients. In the present study, we present our preliminary results after the first 6 months of enrollment. Adult males with NOA without genetic alterations who agreed to participate in the study and signed the required informed consent were included. Sperm retrieval rate (SRr), intra and post-operative complication rate (according to Clavien-Dindo classification), hormonal profile trends were considered as outcomes during the follow-up period.

Results
6 patients were enrolled between March 2022 and June 2022. Median follow-up was 5 months (IQR 3-6). Median age was 40 (IQR 35-44). Preoperative median FSH was 18.3 UI/l (IQR 15 -32) and total Testosterone was 3.95 ng/mL (IQR 2.7-4.9). Overall, SRr occurred in one patient (16.6%) from both sides. In patients with a negative SRr the histopathological report highlighted a Sertoli cells only syndrome (SCOS) in 4 cases and a tubular scleroyalinosis associated with early spermatogenic arrest in the last patient. No intraoperative complications were recorded. As regards postoperative complications, no significant differences were recorded between the two surgical approaches, there was a single case of wound infection (Clavien Dindo I) following the procedure. Considering the operative L-TeSE proved to be faster than m-TeSe with a median saving of 20 minutes (IQR 14-28) for each procedure.

Conclusions
According to our preliminary the two procedures may guarantee comparable outcomes in term of SRr. Additionally, L-Tese may allow to save operative time when compared to the m-Tese apparently.

Conflicts of Interest
The authors declare no conflict of interest.
(197) IS PENILE SIZE IN GRADE 3 ERECTION HARDNESS SCORE (EHS 3) COMPARABLE WITH EHS 4?
Authors: Dr. Manuel Alonso-Isa , Dr. Borja García-Gómez , Dr. Guillermo Celada-Luis , Dr. Alessandro Fiorillo , Dr. Daniel Tueti-Silva , Dr. Esther García-Rojo , Eduard García-Cruz , Javier Romero-Otero 
Published: July 2023

Abstract

Objectives
EHS 3 is defined like: “Penis is hard enough for penetration, but not completely hard” and EHS 4 is defined like: “Penis is completely hard and fully rigid”. In both cases we speak of penile hardness but not of penile size. We aim to analyze if there are significant differences between penile growth in ESH 3 and EHS 4

Methods
We retrospectively review a total of 225 patients from February 2021 to October 2022 who underwent penile ultrasonography with prostaglandin injection (10 mcg). Demographic, vascular and other relevant variables were recorded for analysis. A history of Peyronie disease or penile surgery (excluding postectomy and frenuloplasty) were exclusion criteria. We measured the penile length (in cm) in the flaccid state. After injecting prostaglandin, penile measures were taken only EHS 3 and EHS 4 were included.

Results
Mean age 48 (range 17-98). Mean penis size (flaccid) 10.07cm (range 4-17). Mean erect penile length (EPL) 14.37 (range 9.0-19.5). Mean EPL (EHS 3) 14.05 (range 9.0-19.5). Mean EPL (EHS 4) 14.76 (range 11.0-19.0). Mean penile growth (EHS 3) 42.3 % (range 1.8-279.5) Mean penile growth (EHS 4) 48.5% (range 1.5-107.2).
The Mann-Whitney U test indicates that the difference between penile growth in EHS 3 compared to EHS 4 is statistically significant (p &lt; 0.05). However, difference in growth between EHS3 and EHS 4 is only 6.2%.

Conclusions
Differences in growth between EHS 3 and 4, although statistically significant, are not clinically relevant. Penile growth evaluation could be done together in EHS 3 and 4.

Conflicts of Interest
Authors have no potential conflict of interest to report.